The European Medicines Company (EMA) stated on Monday that it has begun evaluating an utility by Pfizer for its anti-coronavirus drug Paxlovid.
“EMA has began evaluating an utility for a conditional advertising and marketing authorization for the oral antiviral medication Paxlovid,” the EU regulator stated in a press release.
The assertion stated that the regulator may ship its evaluation inside weeks because it had already carried out a preliminary assessment based mostly on laboratory, animal, and medical research.
Following EMA’s advice, the European Fee would formally give the advertising and marketing authorization.
The medication reduces the power of the virus to multiply within the physique.
By treating adults and adolescents with mild-to-moderate signs of COVID-19, the drug can decrease the chance of growing extreme sickness and hospitalization.